Resolution Votes for % of Votes % of Votes cast Total Votes
votes against votes in total votes withheld
cast cast cast as
a %
of
issued
share
capital
1 To receive the             99.86 1,300,153 0.14 952,585,841 72.56 8,944,126
Company's Accounts,            
the Reports of the          
Directors and Auditor  951,285,688
and the Strategic
Report for the year
ended 31 December 2020
2 To confirm dividends 948,459,461 98.72 12,290,505 1.28 960,749,966 73.19 779,685
3 To reappoint 952,398,382 99.15 8,210,440 0.85 960,608,822 73.17 921,116
PricewaterhouseCoopers
LLP as Auditor
4 To authorise the 959,859,984 99.93 712,232 0.07 960,572,216 73.17 956,959
Directors to agree the
remuneration of the
Auditor
5a To re-elect Leif 927,811,941 96.57 32,966,929 3.43 960,778,870 73.19 750,714
Johansson as a
Director
5b To re-elect Pascal 959,330,670 99.85 1,441,425 0.15 960,772,095 73.19 757,539
Soriot as a Director
5c To re-elect Marc 955,828,852 99.52 4,600,836 0.48 960,429,688 73.16 1,099,897
Dunoyer as a Director
5d To re-elect Philip 948,284,819 98.74 12,063,553 1.26 960,348,372 73.15 1,160,972
Broadley as a Director
5e To elect Euan Ashley 952,998,109 99.28 6,906,560 0.72 959,904,669 73.12 1,623,921
as a Director
5f To re-elect Michel 940,774,376 97.96 19,589,264 2.04 960,363,640 73.16 1,165,704
Demaré as a Director
5g To re-elect Deborah 826,293,184 86.04 134,102,115 13.96 960,395,299 73.16 1,140,585
DiSanzo as a Director
5h To elect Diana 959,699,058 99.93 675,091 0.07 960,374,149 73.16 1,154,886
Layfield as a Director
5i To re-elect Sheri 710,781,431 74.03 249,365,290 25.97 960,146,721 73.14 1,388,375
McCoy as a Director
5j To re-elect Tony Mok 958,732,518 99.83 1,606,337 0.17 960,338,855 73.15 1,184,730
as a Director
5k To re-elect Nazneen 950,350,073 99.73 2,544,392 0.27 952,894,465 72.59 8,634,879
Rahman as a Director
5l To re-elect Marcus 828,248,091 86.21 132,435,623 13.79 960,683,714 73.18 832,550
Wallenberg as a
Director
6 To approve the Annual 915,909,189 95.42 43,957,696 4.58 959,866,885 73.12 1,662,608
Report on Remuneration
for the year ended 31
December 2020
7 To approve the 564,935,789 60.19 373,708,277 39.81 938,644,066 71.50 21,415,088
Directors'
Remuneration Policy
8 To authorise limited 930,305,254 96.90 29,777,151 3.10 960,082,405 73.13 1,446,855
political donations
9 To authorise the 817,312,076 85.14 142,701,485 14.86 960,013,561 73.13 1,515,509
Directors to allot
shares
10 To authorise the 939,179,092 98.03 18,824,969 1.97 958,004,061 72.98 3,474,403
Directors to disapply
pre-emption rights
11 To authorise the 932,779,470 97.36 25,292,148 2.64 958,071,618 72.98 3,406,846
Directors to further
disapply pre-emption
rights for
acquisitions and
specified capital
investments
12 To authorise the 942,491,633 98.16 17,676,115 1.84 960,167,748 73.14 1,310,466
Company to purchase
its own shares
13 To reduce the notice 847,834,118 88.31 112,182,050 11.69 960,016,168 73.13 1,462,280
period for general
meetings
14 To amend the rules of 579,132,133 61.72 359,154,356 38.28 938,286,489 71.47 21,721,411
the 2020 Performance
Share Plan

Issued capital

As at 7 May 2021, the number of issued shares of the Company was 1,312,762,006 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

Notes

The Board is pleased that all resolutions have been approved by shareholders at the 2021 AGM. The Board notes the lower levels of support received for Resolutions 5i, 7 and 14. The Board has already engaged with a number of shareholders to understand the reasoning behind their decision not to support these Resolutions and will continue to engage during 2021.

Resolutions 7 and 14 - approval of the Remuneration Policy and changes to the AstraZeneca Performance Share Plan

The Remuneration Committee (the Committee) undertook an in-depth consultation process with the Company's largest investors when developing the revised policy, and were pleased with the positive reception for the proposals. Nonetheless the Committee recognises that a meaningful proportion of shareholders (including those who follow the guidance of their proxy advisors) were not able to support the new policy or the amendments to the 2020 Performance Share Plan rules. The Committee will continue to engage and listen to ensure investors' concerns regarding the approach to executive remuneration are understood.

The Committee acknowledges that it is unusual to seek approval for a revised Remuneration Policy at two consecutive AGMs and that remuneration is a sensitive matter during this pandemic period. Starting with the latter, it is important to emphasise that AstraZeneca has not applied for any Government funded wage subsidies or furlough arrangements around the world. Additionally, the Company has been a world-leading actor in the pandemic response through its non-profit vaccine initiative and other humanitarian actions.

The Committee also wanted to update the Remuneration Policy to acknowledge that the world drastically changed in the last 12 months, and so did AstraZeneca. Our Executive Directors have demonstrated solid and visionary leadership to steer the Company towards delivering another outstanding performance in terms of achieving stretched financial goals, over-delivering pipeline management targets to accelerate innovation, and negotiating new partnerships with great potential. They also initiated an impactful societal, non-profit initiative - in partnership with University of Oxford - as a response to the global pandemic, resulting in the development, production and supply of an effective vaccine in less than a year.

Since their appointment, the Executive Directors have driven a remarkable turnaround in the Company's performance, resulting in a TSR close to 300% over the last eight years and 77% over the last three years, both significantly ahead of our Global and European Pharmaceutical peers.

The Board's approach to reviewing the policy last year still continued to position executive remuneration well below market levels in the global pharmaceuticals industry, and did not accurately reflect AstraZeneca's improved position in the European market. Since that review, given the significantly increased scale and scope of what the CEO and CFO are being asked to deliver, and their continued commitment and undisputed performance, the Board considered it appropriate to take another step to address their market pay positioning in order to retain and incentivise them; and enable succession planning for the future. This decision was taken in the interests of all stakeholders to support the future growth of the Company, and provide us with the flexibility required to reward outstanding achievements with competitive pay for performance packages. 

Resolution 5i - re-election of Sheri McCoy as a Director

The Board understands that some shareholders have expressed concerns regarding Ms McCoy's other directorships and the potential for those to impact her time commitment to AstraZeneca.

The Board believes that Ms McCoy has brought, and continues to bring, considerable business experience and knowledge of the pharmaceutical industry and makes a valuable contribution to the work of the Board and Committees of which she is a member.

In 2020, Ms McCoy attended 96% of the Board and Committee meetings to which she was invited: 14 out of a possible 15 Board meetings, 7 out of 7 Audit Committee meetings and 6 out of 6 Remuneration Committee meetings.

Ms McCoy is currently working to reduce her appointments and intends to reduce her participation to not more than four boards by the 2022 proxy season.

The Board is satisfied that all Directors, including Ms McCoy, continue to make effective and valuable contributions to the Board and continue to devote sufficient time to discharging their responsibilities as Directors of AstraZeneca.

The Board seeks to maintain the highest standards of governance and to ensure an open and transparent dialogue with shareholders. The Board will continue to engage with, and listen to, the Company's shareholders. In accordance with the UK Corporate Governance Code, the Company will publish an update within six months of the AGM.

Additional information

A copy of the resolutions passed at the AGM will be submitted to the National Storage Mechanism in accordance with Listing Rules 9.6.2R and 9.6.3R, and will be available in due course for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca).

AstraZeneca contacts

For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).